Cardiol Therapeutics Inc

CRDLNASDAQ · USD
0.96USD-0.04 (-3.76%)
235

Cardiol Therapeutics Inc (CRDL) Covered Calls

Cardiol Therapeutics Inc trades in the Drug Manufacturers - Specialty & Generic industry with an IV Rank of 100.00%, high versus the past year. CRDL's highest covered call setup is the $2.00 strike expiring Mar 19, 2027, sorted by theoretical annualized return. It's 98.02% out of the money with 128 days to expiration, a 102.97% return until expiration, and a 293.63% theoretical annualized return. Across the setups shown, annualized returns run from 255.29% to 293.63% at strikes between $2.00 and $2.50, with 128 to 218 days to expiration, as of Nov 11, 2026.

Read more

Running CRDL covered calls helps you generate income from Cardiol Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CRDL covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If CRDL stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CRDL covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CRDL covered call is worth writing.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure.

2027-03-191282.0098.020.050.10104.00102.97293.63-4.95+0.2500.05
2027-06-172182.50147.520.054.90154.00152.48255.29-4.95+1.0014.85

As of Nov 11, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryDrug Manufacturers - Specialty & Generic
  • SectorHealthcare
  • IV Rank100.00% High
  • Market cap (M$)121
  • 52 weeks high-57.26%
  • 52 weeks low13.64%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$7.89
    719.83% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-13
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.24
  • EPS growth next 5 years61.01%

As of Nov 13, 2026